Psoriasis Study Shows a Path for Considering US Drug Costs Psoriasis Study Shows a Path for Considering US Drug Costs
Only three of 13 psoriasis biologics appeared to be cost-effective based on US prices in a new analysis. The finding may aid policymakers struggling with drug price negotiations.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 8, 2024 Category: Dermatology Tags: Dermatology Source Type: news
Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis
TUESDAY, March 5, 2024 -- For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and Therapy.Andreas Pinter, M.D., from the University Hospital Frankfurt... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 6, 2024 Category: Pharmaceuticals Source Type: news
New Data on First-Line Psoriasis Drug'Very Reassuring'New Data on First-Line Psoriasis Drug'Very Reassuring '
A higher cumulative dose of methotrexate taken did not increase the risk for liver fibrosis, but excess weight, metabolic syndrome, and diabetes did.Medscape News UK (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 1, 2024 Category: Dermatology Tags: Dermatology Source Type: news
Generic SpA Screening Tool Needed Across Comorbid Diseases Generic SpA Screening Tool Needed Across Comorbid Diseases
A comparison of screening tools for SpA in conditions that commonly co-occur with the disease revealed few screening tool options for patients with uveitis or IBD, compared with psoriasis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 1, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
What Drives Fatigue in Psoriasis and PsA? What Drives Fatigue in Psoriasis and PsA?
Joint pain and itch were key culprits, according to a cross-sectional analysis of Danish data.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 27, 2024 Category: Dermatology Tags: Dermatology Source Type: news
Biologic Treatment for Psoriasis Linked to Lower Mortality Biologic Treatment for Psoriasis Linked to Lower Mortality
Evidence to support the hypothesis that the use of systemic immunomodulatory agents for psoriasis " quenches systemic inflammation and potentially improves " survival is limited, investigators said.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 26, 2024 Category: Cardiology Tags: Dermatology Source Type: news
Doctor shares key symptoms of genital psoriasis - and who is at risk
While psoriasis tends to mainly target your elbows, knees, scalp and lower back, it could also appear on your genitals, a medical expert has warned. (Source: Daily Express - Health)
Source: Daily Express - Health - February 24, 2024 Category: Consumer Health News Source Type: news
EMA Approves Tx for Psoriasis and Other Autoimmune Disorders EMA Approves Tx for Psoriasis and Other Autoimmune Disorders
The biosimilar Pyzchiva is highly similar to Stelara, which was approved in the EU in 2009.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 23, 2024 Category: Dermatology Tags: Dermatology Source Type: news
Tapinarof Under FDA Review for Treating Atopic Dermatitis Tapinarof Under FDA Review for Treating Atopic Dermatitis
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Drug Trials Snapshots: BIMZELX
BIMZELX is an anti-interleukin (IL)-17A and IL-17F monoclonal antibody that is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 15, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
THURSDAY, Feb. 8, 2024 -- For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2024 Category: Pharmaceuticals Source Type: news
High Response Rates in Psoriasis With Oral IL-23 Inhibitor
(MedPage Today) -- An oral interleukin (IL)-23 inhibitor for psoriasis produced 16-week response rates as high as 79% in moderate-to-severe plaque psoriasis, a prospective phase II trial showed.
The drug (JNJ-77242113) achieved response rates... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 7, 2024 Category: Dermatology Source Type: news
Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis
The small-molecule oral investigational agent JNJ-77242113 at the highest dose tested was associated with reductions in psoriasis severity comparable to injectable biologic agents.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 7, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Viral protein fragments may unlock mystery behind serious COVID-19 outcomes
Key takeawaysThere remains no clear explanation for why COVID-19, caused by SARS-CoV-2, can result in severe outcomes or death while other coronaviruses just cause common colds, or why COVID-19 symptoms persist after the coronavirus that causes it has been eliminated.A UCLA-led research team has shown that fragments of the coronavirus may drive inflammation by mimicking the action of specific immune molecules in the body.The findings could contribute to not only the understanding and treatment of COVID-19 but also efforts to detect coronaviruses with the potential to cause pandemics before they become widespread.There are ...
Source: UCLA Newsroom: Health Sciences - January 31, 2024 Category: Universities & Medical Training Source Type: news
Emerging Therapies Foretell New Era for Cutaneous Disorders Emerging Therapies Foretell New Era for Cutaneous Disorders
Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2024 Category: Consumer Health News Tags: Dermatology Source Type: news
